Erik Reinertsen

Erik built and led data science and engineering at Prometheus Biosciences through IPO to $10.8B acquisition by Merck, and evaluated investments at Takeda Ventures. He has published and patented machine learning methods applied to genetic, physiological, and clinical data to predict clinical outcomes and therapeutic response. Erik has a B.S. in Bioengineering from UCLA, a Ph.D. in Biomedical Engineering from the Georgia Institute of Technology, an M.D. from Emory University School of Medicine, and did his postdoctoral fellowship in AI/ML at the Massachusetts Institute of Technology, Massachusetts General Hospital, and Harvard Medical School.